223537-30-2CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C)Cc1ccc(F)cc1CAYJBRBGZBCZKO-BHGBQCOSSA-NRupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
UsesLabelled Rupintrivir. Rupintrivir (formerly AG7088) is an irreversible inhibitor of the human rhinovirus (HRV) 3C protease that has been demonstrated to have in vitro activity against all HRVs tested, consistent with its interaction with a strictly conserved subset of amino acids in the 3C protease.
General DescriptionRupintrivir is an irreversible peptidomimetic inhibitor designed to target human rhinovirus (HRV). It was previously named as AG7088. It has been suggested that rupintrivir may be involved in vitro antiviral activity.
No reaction records under the current filter.
Loading…
223537-30-2DTXSID201028116CHEMBL20210